Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - The Lancet, 2005 - thelancet.com
Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
Synthetic tumor‐specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial
N Jain, JM Reuben, H Kantarjian, C Li… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: Imatinib is the current standard frontline therapy for chronic myelogenous
leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic …
leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic …
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
BD Smith, YL Kasamon, J Kowalski, C Gocke… - Clinical Cancer …, 2010 - AACR
Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity.
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study
JM Rojas, K Knight, L Wang, RE Clark - Leukemia, 2007 - nature.com
Peptides from the e14a2 BCR-ABL junction will elicit T-cell responses in vitro. Here, 19
imatinib treated CML patients in first chronic phase were vaccinated with BCR-ABL peptides …
imatinib treated CML patients in first chronic phase were vaccinated with BCR-ABL peptides …
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
K Cathcart, J Pinilla-Ibarz, T Korontsvit, J Schwartz… - Blood, 2004 - ashpublications.org
A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …
Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia
Z Li, Y Qiao, B Liu, EJ Laska, P Chakravarthi… - Clinical Cancer …, 2005 - AACR
Purpose: To test the feasibility, safety, immunogenicity, and clinical efficacy of an autologous
vaccine of leukocyte-derived heat shock protein 70-peptide complexes (Hsp70PC), in …
vaccine of leukocyte-derived heat shock protein 70-peptide complexes (Hsp70PC), in …
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
J Pinilla-Ibarz, K Cathcart, T Korontsvit… - Blood, The Journal …, 2000 - ashpublications.org
Chronic myelogenous leukemia (CML) presents a unique opportunity to develop therapeutic
strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic …
strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic …
Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
A Burchert, S Wölfl, M Schmidt… - Blood, The Journal …, 2003 - ashpublications.org
Chronic myeloid leukemia (CML) is a clonal disease of hematopoietic stem cells caused by
a reciprocal translocation of the long arms of chromosomes 9 and 22. In human leukocyte …
a reciprocal translocation of the long arms of chromosomes 9 and 22. In human leukocyte …
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly …
MW Deininger, KJ Kopecky, JP Radich… - British journal of …, 2014 - Wiley Online Library
The standard dose of imatinib for newly diagnosed patients with chronic phase chronic
myeloid leukaemia (CP‐CML) is 400 mg daily (IM400), but the optimal dose is unknown …
myeloid leukaemia (CP‐CML) is 400 mg daily (IM400), but the optimal dose is unknown …
Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells
C Arndt, M Von Bonin, M Cartellieri, A Feldmann… - Leukemia, 2013 - nature.com
5 Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU et al. Altered microenvironmental
regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell …
regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell …